ZHAOKE OPHTH-B - VOLUNTARY ANNOUNCEMENT -

INNOVATIVE PRESBYOPIA DRUG YUVEZZI APPROVED FOR USE AT BOAO SUPER HOSPITAL AS A CLINICALLY URGENT IMPORTED DRUG

Limited (the "Company") on a voluntary basis.

The Board of the Company is pleased to announce that, on June 26, 2026, the Company's

innovative presbyopia drug, YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution (2.75%/0.1%)), has been approved by the Hainan Provincial Medical Products Administration for use at Boao Super Hospital as a clinically urgent imported drug. YUVEZZI™ is the first approved innovative drug for presbyopia in China. The approval

creates an important pathway for patients in China to gain earlier access to innovative therapies for presbyopia that are already available internationally.

This approval is granted in accordance with the Decision of the State Council on Temporarily Adjusting the Implementation of the Regulations for Implementation of the

Drug Administration Law of the People's Republic of China in the Hainan Boao Lecheng International Medical Tourism Pilot Zone. Applications submitted by medical institutions within the pilot zone for the import of a small quantity of clinically urgently needed medicines (excluding vaccines) shall be examined and approved by the People's Government of Hainan

Province. Medicines imported upon approval shall only be used for specific medical purposes at designated medical institutions.

– 1 –

ABOUT YUVEZZI™ (CARBACHOL AND BRIMONIDINE TARTRATE

OPHTHALMIC SOLUTION)

YUVEZZI™ is a once-daily, preservative-free pupil-modulating eye drop formulation that can be stored at room temperature, designed to restore near vision lost due to presbyopia.

YUVEZZI™ is a fixed-dose combination of carbachol, a cholinergic agent, and brimonidine tartrate, an α2-adrenergic receptor agonist. This novel therapy induces pupil constriction, creating a pinhole effect that allows only centrally focused light rays to enter the eye, thereby enhancing image sharpness at near and intermediate distances.

YUVEZZI™ was in-licensed from the Company's U.S. partner, Tenpoint Therapeutics Ltd. ("Tenpoint"). In January 2026, Tenpoint received U.S. Food and Drug Administration ("FDA") approval for YUVEZZI™ as a once-daily, dual-agent eye drop for the treatment of presbyopia, a condition characterized by the gradual loss of close-up vision that typically

begins arounds age 45.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot

guarantee that it will ultimately develop, or commercialize carbachol and brimonidine tartrate ophthalmic solution (YUVEZZI™) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Zhaoke Ophthalmology Limited Dr. Li Xiaoyi Chairman

Hong Kong, July 7, 2026

As at date of this announcement, the Board of the Company comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian

Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.

– 2 –